---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-038157"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:51:44.851432+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences awards CEO Barry $355K bonus tied to simufilam TSC epilepsy exploration

## Summary
- Board approved cash bonuses for 2025: CEO Richard Barry $355,000, CFO Eric Schoen $215,000.
- Performance measures include exploring simufilam for Tuberous Sclerosis Complex-related epilepsy.
- Other goals: building TSC expertise team and budgeting/expense management.
- Bonuses reflect contributions in advancing new potential indication for simufilam beyond Alzheimer's.

## SEC filing metadata
- accession: 0001437749-25-038157
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774925038157/0001437749-25-038157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774925038157/sava20251217_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-038157
- JSON: https://secwatch.observer/filing/0001437749-25-038157.json
- Plain text: https://secwatch.observer/filing/0001437749-25-038157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.